CBIO Crescent Biopharma, Inc.
$13.50▲ +1.73%
Healthcare
Other
After hours
$13.25▼ -1.84%
Oct 28, 4:46 PM ET
Volume 238.7K
Avg Volume (10D) 263.0K
Key Metrics & Fundamentals
Market Cap
$501.48M
P/E Ratio
–
Div Yield
0.00%
52W Range
8.72 - 27.41
% vs 50 MA
-14.25%
% vs 200 MA
-14.92%
RSI-14
45.8
MACD Histogram
+0.1800
Beta (1Y vs SPY)
0.95
Free Cash Flow
-$19.48M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$24.77M
COGS
–
Operating Exp
$26.36M
Operating Income
-$26.36M
EBIT
-$26.36M
Pretax Income
-$24.84M
Net Income
-$24.84M
EPS (Diluted)
-0.74
Price & Volume History
Loading chart…
Recent News
Crescent Reports Over 125 Patients Dosed in ASCEND Trial
MT Newswires · Oct 15, 2026 5:51 PM ET
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
GlobeNewswire · Oct 15, 2026 4:15 PM ET
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire · Oct 6, 2026 4:15 PM ET
HC Wainwright Upgrades Crescent Biopharma to Buy From Neutral, Price Target is $36
MT Newswires · Oct 6, 2026 6:32 AM ET
Crescent Biopharma's Investigational New Drug Application for CR-002 to Treat Solid Tumors Cleared by FDA
MT Newswires · Oct 5, 2026 8:27 AM ET
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
GlobeNewswire · Oct 5, 2026 7:30 AM ET
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire · Sep 25, 2026 4:15 PM ET
Crescent's Tumor Treatment Validated by Akeso Trial Results, Wedbush Says
MT Newswires · Sep 14, 2026 12:00 PM ET
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Investor's Business Daily · Sep 3, 2026 4:51 PM ET
Crescent Biopharma to Present at September Investor Conferences
GlobeNewswire · Sep 3, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See CBIO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.